Stock Pulse
Thermo Fisher Scientific (TMO) demonstrated strong Q4 2024 financial performance with 5% revenue growth reaching $11.4 billion and substantial free cash flow exceeding $7.3 billion [1], [3], [6], [7]. The company acquired SOLV's Purification and Filtration business for $4.1 billion, strengthening its bioprocessing capabilities [1], [3]. Despite macroeconomic uncertainties and declining COVID-19 testing demand impacting past stock performance [2], [5], TMO launched new products like the Krios 5 Cryo-TEM, demonstrating continued innovation [4], [9]. Analysts remain bullish on long-term growth, citing TMO's diverse offerings and leadership in the life sciences sector [1], with at least one maintaining a Buy rating [3]. However, competition from AI stocks and potential pricing pressures represent ongoing challenges [1], [3], [6].